What is the pregnancy category of omeprazole (Proton Pump Inhibitor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

There are no adequate and well-controlled studies with omeprazole in pregnant women. The FDA drug label does not answer the question.

From the Research

Omeprazole is classified as pregnancy category C by the FDA, and its use during pregnancy is generally considered acceptable, especially after the first trimester, when the benefit outweighs the risk. This classification is based on animal studies that have shown adverse effects on the fetus, but there are no adequate well-controlled studies in humans 1. However, potential benefits may warrant use of omeprazole during pregnancy despite potential risks.

Key Considerations

  • If omeprazole is needed during pregnancy, it's generally considered acceptable to use, especially after the first trimester when the benefit outweighs the risk.
  • For pregnant women requiring treatment for acid-related disorders, lifestyle modifications should be tried first, followed by antacids or sucralfate.
  • If these are insufficient, H2-blockers like ranitidine are typically preferred as first-line medication therapy before considering proton pump inhibitors like omeprazole.
  • The classification reflects a cautious approach rather than proven harm, as real-world experience with omeprazole in pregnancy has not demonstrated significant adverse outcomes, as shown in a multicentre prospective controlled study 1.

Clinical Decision Making

Healthcare providers should always evaluate the individual clinical situation when prescribing omeprazole during pregnancy, considering the potential benefits and risks. A study published in 2005 found that the rate of major congenital anomalies did not differ between women exposed to omeprazole and a control group 1. This suggests that omeprazole may be safer than previously thought, but more research is needed to confirm this.

Summary of Evidence

  • A multicentre prospective controlled study found that the rate of major congenital anomalies did not differ between women exposed to omeprazole and a control group 1.
  • Another study found that omeprazole is well tolerated and does not cause severe side effects in pregnant women or their newborns 2.
  • A record-linkage analysis in Tayside, Scotland, found that prescribing of Category C drugs, including omeprazole, was common during pregnancy, but the levels of prescribing of drugs that are known to be harmful were low 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.